Business Wire

BearingPoint Study: Does Your Data Underpin Resilience or Undermine It?

Share

Management and technology consultancy BearingPoint has created a deep dive study on enterprise data resilience. This paper is the first of five companion pieces to the 2021 ‘Can you thrive under pressure’ study, the analysis of over 5,000 projects leading to the ranking of 150 best practice resilient organizations. BearingPoint has also created a resilience benchmarking tool that enables any organization to assess their own alignment with the five fundamental pillars of resilience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005860/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BearingPoint Study: Does your data underpin resilience or undermine it? Key results at a glance.

BearingPoint believe data and analytic resilience is undermined by lack of people empowerment, as 65% of organizations lack data literacy and 56% face cultural resistance to change. Other obstacles impacting data led change initiatives included lack of resources and funding (33%) and disconnect with the business strategy (20%). BearingPoint’s study also concludes that implementation is not easy. The study has found that organizations need a structured vision combined with a disciplined approach e.g., an effective data strategy: without it organizations will fail to generate benefits from investment.

BearingPoint’s research indicates that organizations’ data strategy can only be successful if it is underpinned by the five dimensions of a resilient organization:

1. Understand your data ecosystem: You need the right datapoints to take the right decisions

2. Empower your people for change: Make sure your people interact positively in the data value chain

3. Align data centricity with business outcomes: Steer your data journey so it is agile and focused on business outcomes

4. Use technology to improve agility: Select the architecture that will best support your business model

5. Build proper and effective governance: Data-centricity needs to involve your entire organization, not just leadership

Jan Henderyckx, Partner at BearingPoint asks “is data a hobby or holy grail in your organization? We are witnessing the start of a new industrial revolution, fuelled by data rather than coal. But we believe effective data-centric transformation is not about size, but attitude. Our research shows companies will only survive and thrive if they adopt a rounded, well-balanced and progressive approach across these five dimensions. All are vital. Only by delivering on all of them, your organization will become resilient to change. As all firms, in all sectors must understand that data needs to be at the heart of their business strategy.”

All categories of organization type that BearingPoint studied had room for improvement in the area of data resilience with organizations of all types showing maturing or developing data centricity. BearingPoint observed that Government organizations have lower data resilience scores than privately held and publicly listed companies. According to the study, a reason for this may be that privately held companies may have more scope to execute fast decision making (governance).

Jan Henderyckx will be discussing the study’s finding as the Plenary Keynote speaker at: Creating Data Centric Business Resilience at IRMUK Data Governance Conference Europe, May 18, 2022, in London.

“We are living in a world in which it is increasingly more important to be able to adapt to the changing environment. Your decisions should be based on facts rather than assumptions. Companies that put data centricity at the core of their strategy are going to create value. Especially if they apply a comprehensive approach to all dimensions that impact the implementation of a data strategy,’’ says Jan Henderyckx.

About the study

BearingPoint analyzed over 5,000 client projects, built a model to assess how organizations create successful long-term transformations, and then calibrated resilience profiles based on five observed characteristics. You can download the study here to find out more: https://www.bearingpoint.com/en-gb/insights-events/insights/data-must-be-at-the-heart-of-your-business-strategy/

About BearingPoint

BearingPoint is an independent management and technology consultancy with European roots and a global reach. BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.

www.bearingpoint.com
www.linkedin.com/company/bearingpoint
@BearingPoint

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact
Alexander Bock
Global Manager Communications
Telephone: +49 89 540338029
Email: alexander.bock@bearingpoint.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye